Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Jonathan Rosenberg, Renaud Sabatier, Armelle Viceneux, Thibault de La Motte Rouge, Stephane Champiat, Loic Lebellec, Philippe Barthélémy, Guru Sonpavde, Xin Gao, Scot Niglio, Tian Zhang, Craig Gedye, Matthew Galsky, Matthew Milowsky, Melissa Reimers, Andrew Weickhardt, Enrique Grande, Daniel E. Castellano, Mehmet Bilen, Amita Patnaik, Robert Zerbib, Minna Balbas, Xiaojian Xu, Kaitlyn Aptaker, Arjun V. Balar, Ahmad H. Awada
Institutions: Memorial Sloan Kettering Cancer Center, Institut Paoli-Calmettes, Centre Léon Bérard, Centre Eugène Marquis, Institut Gustave Roussy, Centre Oscar Lambret, Institut de Cancérologie Strasbourg, Massachusetts General Hospital, New York University, The University of Texas Southwestern Medical Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of North Carolina at Chapel Hill, Washington University in St. Louis, Austin Hospital, Austin Health, MD Anderson Cancer Center Madrid, Hospital Universitario 12 De Octubre, Emory University, Winship Cancer Institute, South Texas Accelerated Research Therapeutics, Loxo Oncology at Lilly (United States), Institut Jules Bordet
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4393988915